The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on m...

Descripción completa

Detalles Bibliográficos
Autores principales: Liberini, Virginia, Huellner, Martin W., Grimaldi, Serena, Finessi, Monica, Thuillier, Philippe, Muni, Alfredo, Pellerito, Riccardo E., Papotti, Mauro G., Piovesan, Alessandro, Arvat, Emanuela, Deandreis, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763988/
https://www.ncbi.nlm.nih.gov/pubmed/33322819
http://dx.doi.org/10.3390/diagnostics10121083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763988/
https://www.ncbi.nlm.nih.gov/pubmed/33322819
http://dx.doi.org/10.3390/diagnostics10121083

Ejemplares similares